ReviewClinical reviews in allergy & immunology2010
Intravenous immunoglobulin in lupus panniculitis.
Review in Clinical reviews in allergy & immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Cutaneous lupus erythematosus: A review of the literature.International journal of women's dermatology · 2019Review
- Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.Wiener medizinische Wochenschrift (1946) · 2018Review
- Lupus profundus limited to a site of trauma: Case report and review of the literature.International journal of women's dermatology · 2017Article
- Lupus erythematosus panniculitis resistant to standard treatment, complicated with macrophage activation syndrome.Postepy dermatologii i alergologii · 2017Article
- Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study.Dermatology reports · 2015Article
- Indications for IVIG in rheumatic diseases.Rheumatology (Oxford, England) · 2015Review
- Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.The Journal of clinical and aesthetic dermatology · 2013Article
- The future of autoimmunity.Clinical reviews in allergy & immunology · 2012Article
- Mechanisms and pathophysiology of autoimmune disease.Clinical reviews in allergy & immunology · 2012Article
- Update on management of connective tissue panniculitides.Dermatologic therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a disease of unknown cause that may involve one or many organ or systems. Skin involvement is a major feature in this disease, and a wide variety of skin conditions may be present. Lupus erythematosus panniculitis (LEP) constitutes a rare form of cutaneous lupus characterized by recurrent nodular or plaque lesions that can vary from a benign and mild course to a more disfiguring disease. Initial therapy includes corticosteroids, antimalarials, and azathioprine and, in refractory cases, two antimalarials in association, mycophenolate mofetil, or other immunomodulators. Intravenous immuglobulin (IVIG) is used in many autoimmune disorders, like in SLE, although clinical trials have not yet taken place. In this report, we review skin manifestations of SLE and their treatment, IVIG, and finally a case of LEP successfully treated with IVIG when other therapy modalities failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.